Please wait a minute...
6TMR Modern Herbal Medicine  2019, Vol. 2 Issue (1): 3-10    DOI: 10.12032/TMRmhm2017A39
Orginal Article     
Clinical metabolic analysis combined with traceability of biosynthetic pathway: a new approach to quality marker of Chinese materia medica
Yang Zhi-Rui1#, Wang Ai-Ting1#, Liu Juan1,2,3#, Yang Xin-Yu1, Wang Xiao-Fang1, Zhang Lei1, Guo Na4, Zi Jia-Chen5, Peng Cheng6, Yan Shu-Xun7, Yan Dan1,2,3,*()
1 Beijing Shijitan Hospital, Capital Medical University, Beijing, China
2 Beijing Key Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, Beijing, China
3 International Cooperation & Joint Laboratory of Bio-characteristic Profiling for Evaluation of Rational Drug Use, Beijing, China;
4 Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China
5 JiNan University, Guangzhou, China
6 Chengdu University of Traditional Chinese Medicine, Chengdu, China
7 The first affiliated hospital, Henan University of China Medicine, Zhengzhou, China.
Download: HTML     PDF(920KB)
Export: BibTeX | EndNote (RIS)      

Quality marker (Q-marker) of Chinese materia medica (CMM) plays an important role in quality control of CMM products. However, its research strategy and technique remain unclear. Based on the fact that quality standard of CMM should be associated with clinical efficacy, taking Jinqi Jiangtang tablet treating type 2 diabetes as an example, the Q-marker related to activity via the reverse analysis of drug metabolism in clinic and traceability of botanic biosynthetic pathways is discovered and validated. Therefore, we proposed a new research strategy of Q-marker of CMM with "Discovery of clinical active constituents as guidance, Reverse analysis of metabolic transformations as link, and Traceability of biosynthesis pathways as key", to improve quality control of CMM products.

Highlights:
"Discovery of clinical active constituents as guidance, Reverse analysis of metabolic transformations as link, and Traceability of biosynthesis pathways as key", a new research strategy for discovering quality marker of Chinese materia medica (CMM), promotes quality standard of CMM.



Key wordsChinese materia medica      Quality marker      Clinical metabolic analysis      Biosynthetic pathway      Jinqi Jiangtang Tablet      Type 2 diabetes     
Published: 25 January 2019
Fund:  This work was supported by the National Natural Science Foundation of China (81773891), the National Great New Drugs Development Project of China (2017ZX09301-040), the Beijing Natural Science Foundation (7162092), Beijing Talents Project (2017A19), Beijing Municipal Science & Technology Commission (XMLX201704, Z161100000516074), the Open Research Fund of the State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicinal Resources. The funding sources were not involved in study design, data collection or analysis, writing of the manuscript or the decision to publish the results
Corresponding Authors: Yan Dan     E-mail: yd277@126.com.
Cite this article:

Yang Zhi-Rui, Wang Ai-Ting, Liu Juan, Yang Xin-Yu, Wang Xiao-Fang, Zhang Lei, Guo Na, Zi Jia-Chen, Peng Cheng, Yan Shu-Xun, Yan Dan. Clinical metabolic analysis combined with traceability of biosynthetic pathway: a new approach to quality marker of Chinese materia medica. 6TMR Modern Herbal Medicine, 2019, 2(1): 3-10. doi: 10.12032/TMRmhm2017A39

URL:

https://www.tmrjournals.com/mhm/EN/10.12032/TMRmhm2017A39     OR     https://www.tmrjournals.com/mhm/EN/Y2019/V2/I1/3

Figure 1 The biosynthetic pathway of berberine from Coptis chinensis.
The red boxes represent the key intermediates including (S)-scoulerine and (S)-tetrahydrocolumbamine, which are potential Q-marker for quality control of Coptis chinensis from Jiangtang Tablet. The red arrows indicate the reverse analysis strategy based on metabolic and biosynthetic pathway proposed in this article. The blue arrows indicate the regular metabolic and biosynthetic pathway.
Figure 2 The new approach strategy for quality marker of Chinese materia medica.
Figure 3 Metabolites of astragalus saponins in Jinqi Jiangtang Tablet from patients’ serums
The red arrows indicate the reverse analysis strategy based on metabolic and biosynthetic pathway proposed in this article. The blue arrows indicate the regular metabolic and biosynthetic pathway.
Figure 4 The Q-marker of JQJTT and its innovative research approach
JQJTT, Jinqi Jiangtang Tablets; Q-marker, quality marker; UPLC, ultra-performance liquid chromatography; UPLC-MS/MS, ultra-performance liquid chromatography tandem mass spectrometry; STZ, streptozocin; HFD, high-fat diet; FBG, fasting blood glucose; PBG, postprandial blood glucose; OGTT, oral glucose tolerance test.
1.   Liu CX, Cheng YY, Guo DA, et al. A new concept on quality marker for quality assessment and process control of Chinese medicines. Chin Herb Med, 2017. 9: 3-13.
doi: 10.1016/S1674-6384(17)60070-4
2.   Yue SJ, Liu J, Feng WW, et al. System pharmacology-based dissection of the synergistic mechanism of Huangqi and Huanglian for diabetes mellitus. Front Pharmacol 2017. 8: 694.
doi: 10.3389/fphar.2017.00694 pmid: 29051733
3.   Gao LH, Liu Q, Liu SN, et al. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice. J Ethnopharmacol 2014. 151: 675-685.
doi: 10.1016/j.jep.2013.11.024 pmid: 24286962
4.   Chao M, Zou D, Zhang Y, et al. Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocr, 2009. 36(2): 268.
doi: 10.1007/s12020-009-9222-y pmid: 19728183
5.   Zhong Y, Zhu J, Yang Z, et al. Q-marker based strategy for CMC research of Chinese medicine: A case study of Panax Notoginseng saponins. Phytomedicine, 2018. 44: 129-137.
doi: 10.1016/j.phymed.2018.01.023 pmid: 29452723
6.   Liao M, Shang H, Li Y, et al. An integrated approach to uncover quality marker underlying the effects of Alisma orientale on lipid metabolism, using chemical analysis and network pharmacology. Phytomedicine, 2018. 45: 93-104.
doi: 10.1016/j.phymed.2018.04.006
7.   Shi JM, Han WL, Ye WC, et al. Study on chemical constituents of Corydalis yanhusuo W.T.Wang. Nat Prod Res Dev (Chin), 2011. 23: 647-651.
8.   Feng WW, Zhang Y, Tang JF, et al. Combination of chemical fingerprinting with bioassay, a preferable approach for quality control of Safflower Injection. Anal Chim Acta, 2018. 1003:56-63.
doi: 10.1016/j.aca.2017.11.069 pmid: 29317030
9.   Yan D, Xiong Y, Ma LN, et al. Proposal on establishment of quality evaluation pattern and proper mode for Chinese materia medica based on clinical efficacy. Chin Tradit Herbal Drugs (Chin), 2013. 44(1): 1-5.
doi: 10.7501/j.issn.0253-2670.2013.01.001
10.   Reardon S.A mouse’s house may ruin experiments: Environmental factors lie behind many irreproducible rodent experiments. Nature, 2016. 530: 264.
doi: 10.1038/nature.2016.19335
11.   Yan D, Liu J, Wang AT, et al. Exploring research ideas of mechanism of dominant diseases in traditional Chinese medicine based on evidence-based medicine. Chin J Chin Mater Med (Chin), 2018. 13: 2633-2638.
12.   Zi J, Mafu S, Peters RJ.To gibberellins and beyond! Surveying the evolution of (Di) terpenoid metabolism. Annu Rev Plant Biol, 2014. 65(1): 259-286.
doi: 10.1146/annurev-arplant-050213-035705 pmid: 4118669
13.   He SM, Liang YL, Cong K, et al. Identification and characterization of genes involved in benzylisoquinoline alkaloid biosynthesis in coptis species. Front Plant Sci, 2018. 9: 731.
doi: 10.3389/fpls.2018.00731 pmid: 29915609
14.   Kojima M, Uritani I.Studies on chlorogenic acid biosynthesis in sweet potato root tissue in special reference to the isolation of a chlorogenic acid intermediate. Plant Physiol, 1973. 51: 768-771.
doi: 10.1104/pp.51.4.768 pmid: 16658406
15.   Moses T, Papadopoulou KK, Osbourn A.Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives. Crit Rev Biochem Mol Biol, 2014. 49: 439-462.
doi: 10.3109/10409238.2014.953628 pmid: 4266039
16.   Ma Y, Guo J, Mao YP, et al. Analysis for biosynthetic pathways of active constituents in medicinal plants and its availability. Chin J Tradit Chin Med Pharm, 2017. 32: 2079-2083.
17.   Song JJ, Wang Q, Du M, et al. Casein glycomacropeptide-derived peptide IPPKKNQDKTE ameliorates high glucose-induced insulin resistance in HepG2 cells via activation of AMPK signaling. Mol Nutr Food Res, 2017. 61: 1600301.
doi: 10.1002/mnfr.201600301 pmid: 27506476
18.   Mansor LS, Gonzalez ER, Cole MA, et al. Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovasc Diabetol, 2013. 12:136-136.
doi: 10.1186/1475-2840-12-136 pmid: 3849358
[1] Kao Hsiu-Ying, Jiang Yong. Survey of dose-effect relationship in Chinese materia medica[J]. 6TMR Modern Herbal Medicine, 2018, 1(4): 249-258.